-
公开(公告)号：US09943580B2
公开(公告)日：2018-04-17
申请号：US15023653
申请日：2014-09-11
申请人： STC.UNM , LEIDOS, INC
发明人： David S. Peabody , Bryce Chackerian , James Pannucci , Gabriel M. Gutierrez , Amy Rene Noe , Scott Budd Winram , Steve Chienwen Huang
CPC分类号： A61K39/015 , A61K35/76 , A61K39/39 , A61K2039/5256 , A61K2039/5258 , A61K2039/55566 , C07K2319/40 , C12N7/00 , C12N15/1037 , C12N2795/18122 , C12N2795/18123 , C12N2795/18134 , Y02A50/412
摘要： Embodiments are directed to malaria vaccines comprising a bacteriophage VLP displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.
-
公开(公告)号：US11987646B2
公开(公告)日：2024-05-21
申请号：US17497069
申请日：2021-10-08
申请人： Leidos, Inc.
发明人： Gabriel M. Gutierrez , James Pannucci , Michael Ryan Weil , Timothy W. Phares , Vinayaka Kotraiah , Cecille D. Browne , Peter J. Buontempo
摘要： This disclosure provides peptides which can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US11033622B2
公开(公告)日：2021-06-15
申请号：US15989750
申请日：2018-05-25
申请人： Leidos, Inc.
IPC分类号： A61K39/395 , C12N15/00 , C07K7/06 , C07K14/705 , C07K16/28 , C07K7/08 , A61K39/39 , A61P35/00 , A61K31/7105 , A61K35/17 , A61K39/00 , A61K45/06 , A61K38/00 , A61K35/76 , A61P33/06 , A61P31/04
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US10799555B2
公开(公告)日：2020-10-13
申请号：US15906481
申请日：2018-02-27
申请人： Leidos, Inc.
IPC分类号： A61K38/10 , A61K39/015 , A61K38/16 , A61K39/00 , A61K35/17 , A61K38/19 , A61P33/06 , A61P31/20 , A61P37/04 , A61P35/04 , A61K45/06 , C07K7/08 , C07K14/00 , A61K39/39 , A61K48/00
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US10098950B2
公开(公告)日：2018-10-16
申请号：US15705333
申请日：2017-09-15
申请人： Leidos, Inc.
IPC分类号： A61K6/00 , A61K39/00 , A61K39/002 , A61K39/015 , A61K39/395 , A61K45/00 , A61K45/06 , C07K1/00 , C07K16/00 , C07K16/18 , C07K16/20 , A61K39/39 , A61K38/16 , A61K38/10 , C07K7/08
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
公开(公告)号：US20210275669A1
公开(公告)日：2021-09-09
申请号：US17317985
申请日：2021-05-12
申请人： Leidos, Inc.
IPC分类号： A61K39/395 , C12N15/00 , C07K7/06 , C07K14/705 , C07K16/28 , C07K7/08 , A61K39/39 , A61P35/00 , A61K31/7105 , A61K35/17 , A61K39/00 , A61K45/06
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US20200369766A1
公开(公告)日：2020-11-26
申请号：US16879884
申请日：2020-05-21
申请人： Leidos, Inc.
IPC分类号： C07K16/28 , C12N15/11 , A61K39/395 , A61K45/06
摘要： This disclosure provides peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.
-
公开(公告)号：US20180339044A1
公开(公告)日：2018-11-29
申请号：US15989750
申请日：2018-05-25
申请人： Leidos, Inc.
IPC分类号： A61K39/395 , A61K45/06 , A61P35/00 , A61K35/17 , A61K39/00 , A61K31/7105
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US20180200328A1
公开(公告)日：2018-07-19
申请号：US15906481
申请日：2018-02-27
申请人： Leidos, Inc.
IPC分类号： A61K38/10 , A61K39/39 , A61K39/015 , A61K38/16 , A61K39/00 , A61K35/17 , A61K38/19 , A61P33/06 , A61P31/20 , A61P37/04 , A61P35/04 , A61K45/06 , C07K7/08 , C07K14/00
CPC分类号： A61K38/10 , A01K2227/105 , A01K2267/0331 , A01K2267/0337 , A61K35/17 , A61K38/16 , A61K38/19 , A61K39/0011 , A61K39/015 , A61K39/39 , A61K45/06 , A61K48/00 , A61P31/20 , A61P33/06 , A61P35/04 , A61P37/04 , C07K7/08 , C07K14/00
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
-
公开(公告)号：US20240075131A1
公开(公告)日：2024-03-07
申请号：US18388036
申请日：2023-11-08
申请人： Leidos, Inc.
CPC分类号： A61K39/39 , A61K38/10 , A61K38/16 , A61K39/0011 , A61K39/015 , C07K7/08 , A61K2039/55516 , Y02A50/30
摘要： This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.018 秒)
